Literature DB >> 30465110

Digital quantification of KI-67 in breast cancer.

María Del Rosario Taco Sanchez1, Teresa Soler-Monsó2,3, Anna Petit2, Juan Azcarate2, Alba Lasheras2, Carmen Artal2, Miguel Gil3, Catalina Falo3, María Jesús Pla4, Xavier Matias-Guiu5.   

Abstract

Ki-67 proliferative index (Ki-67) is a predictive and prognostic factor in breast cancer (BC). However, some international committees do not recommend its use in routine practice due to insufficient clinical evidence and lack of standardisation and assessment method reproducibility. Scoring of Ki-67 by digital pathology may contribute to overcome these drawbacks. We evaluated 136 core biopsies of BC patients and calculated the correlation of Ki-67 scored by two breast pathologists with two methods, eyeballing visual assessment (EB) on the microscope and digital image analysis (DI), both assessed from hot spot areas (HS) and the average between hot and cold spot areas (AVE). Good and higher correlation between pathologists was observed for HS using DI in comparison to EB (0.861 vs. 0.828). Correlation in HS with both methods was very similar in homogeneous tumours (0.869 vs. 0.866). Lower correlation was found in heterogeneous tumours if EB was used instead of DI (0.691 vs. 0.838). Good agreement with DI in AVE areas was observed in both homogenous and heterogeneous tumours (0.898 and 0.887). Concordance of tumour molecular profiles based on Ki-67 was better using DI in comparison to EB (Kappa index, 0.589 vs. 0675). Whereas EB and DI were alike in homogeneous tumour, DI improved agreement in heterogeneous tumours, particularly in AVE areas. Subgroup analysis for tumour grades also showed improvement of correlation by DI in AVE areas in all G1/G2/G3 groups. Digital pathology using AVE method can be useful for Ki-67 scoring in daily practice, especially in heterogeneous and G2 tumours, by a substantial improvement of agreement between observers and results accuracy.

Entities:  

Keywords:  Breast cancer; Digital analysis; Immunohistochemistry; Ki-67; Prognosis; Reproducibility

Mesh:

Substances:

Year:  2018        PMID: 30465110     DOI: 10.1007/s00428-018-2481-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  18 in total

1.  High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.

Authors:  Carmen Criscitiello; Davide Disalvatore; Michele De Laurentiis; Lucia Gelao; Luca Fumagalli; Marzia Locatelli; Vincenzo Bagnardi; Nicole Rotmensz; Angela Esposito; Ida Minchella; Sabino De Placido; Michele Santangelo; Giuseppe Viale; Aron Goldhirsch; Giuseppe Curigliano
Journal:  Breast       Date:  2013-12-04       Impact factor: 4.380

2.  Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study.

Authors:  Yoshiki Mikami; Takayuki Ueno; Kenichi Yoshimura; Hitoshi Tsuda; Masafumi Kurosumi; Shinobu Masuda; Rie Horii; Masakazu Toi; Hironobu Sasano
Journal:  Cancer Sci       Date:  2013-09-06       Impact factor: 6.716

Review 3.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

Review 4.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

5.  Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.

Authors:  Einar Gudlaugsson; Ivar Skaland; Emiel A M Janssen; Rune Smaaland; Zhiming Shao; Anais Malpica; Feja Voorhorst; Jan P A Baak
Journal:  Histopathology       Date:  2012-09-11       Impact factor: 5.087

6.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Authors:  Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2011-09-29       Impact factor: 13.506

7.  Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.

Authors:  S Fasanella; E Leonardi; C Cantaloni; C Eccher; I Bazzanella; D Aldovini; E Bragantini; L Morelli; L V Cuorvo; A Ferro; F Gasperetti; G Berlanda; P Dalla Palma; M Barbareschi
Journal:  Diagn Pathol       Date:  2011-03-30       Impact factor: 2.644

8.  Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.

Authors:  Juho Konsti; Mikael Lundin; Heikki Joensuu; Tiina Lehtimäki; Harri Sihto; Kaija Holli; Taina Turpeenniemi-Hujanen; Vesa Kataja; Liisa Sailas; Jorma Isola; Johan Lundin
Journal:  BMC Clin Pathol       Date:  2011-01-25

9.  Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer.

Authors:  Z M A Mohammed; D C McMillan; B Elsberger; J J Going; C Orange; E Mallon; J C Doughty; J Edwards
Journal:  Br J Cancer       Date:  2012-01-03       Impact factor: 7.640

10.  How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.

Authors:  Zsuzsanna Varga; Joachim Diebold; Corina Dommann-Scherrer; Harald Frick; Daniela Kaup; Aurelia Noske; Ellen Obermann; Christian Ohlschlegel; Barbara Padberg; Christiane Rakozy; Sara Sancho Oliver; Sylviane Schobinger-Clement; Heide Schreiber-Facklam; Gad Singer; Coya Tapia; Urs Wagner; Mauro G Mastropasqua; Giuseppe Viale; Hans-Anton Lehr
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

View more
  7 in total

1.  Effects of BAP1, Ki-67 index, and Id-1 in patients with clear cell renal carcinoma and their correlation with clinical features and prognosis.

Authors:  Jing Yang; Chunyu Gong; Juan Zhao; Lan Chen; Xuefeng Mei; Guangsen Li; Jian Cai
Journal:  Transl Androl Urol       Date:  2020-10

2.  Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer.

Authors:  Laura Pons; Laura Hernández-León; Ahmad Altaleb; Esperança Ussene; Roman Iglesias; Ana Castillo; Paula Rodríguez-Martínez; Eva Castella; Vanesa Quiroga; Eudald Felip; Beatriz Cirauqui; Mireia Margelí; Pedro Luis Fernández
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

3.  Ki-67 Proliferation Index Assessment in Gastroenteropancreatic Neuroendocrine Tumors by Digital Image Analysis With Stringent Case and Hotspot Level Concordance Requirements.

Authors:  Sarag A Boukhar; Matthew D Gosse; Andrew M Bellizzi; Anand Rajan K D
Journal:  Am J Clin Pathol       Date:  2021-09-08       Impact factor: 2.493

4.  Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention.

Authors:  Hongkun Wang; Honggang Liu; Jun Li; Shuanyu Wei; Xiaojun Liu; Huili Wan; Peiming Zheng; Huixia Zheng
Journal:  Onco Targets Ther       Date:  2020-12-16       Impact factor: 4.147

5.  Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models.

Authors:  Long Chen; Jing Zhang; Xinjing Wang; Yu Li; Lu Zhou; Xiongxiong Lu; Guoqiang Dong; Chunquan Sheng
Journal:  Acta Pharm Sin B       Date:  2021-07-19       Impact factor: 11.413

6.  Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group.

Authors:  Ceren Boyaci; Wenwen Sun; Stephanie Robertson; Balazs Acs; Johan Hartman
Journal:  Biomolecules       Date:  2021-10-30

7.  Artificial intelligence-assisted interpretation of Ki-67 expression and repeatability in breast cancer.

Authors:  Lina Li; Dandan Han; Yongqiang Yu; Jinze Li; Yueping Liu
Journal:  Diagn Pathol       Date:  2022-01-30       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.